Veloxis Pharmaceuticals has agreed to pay $46 million to resolve allegations of kickbacks related to its immunosuppressant drug, Envarsus XR. The settlement comes after the U.S. government accused the company of engaging in schemes that unlawfully promoted the use of its drug through financial incentives to healthcare providers. These practices allegedly involved improper payments and perks to encourage increased prescriptions, leading to concerns about patient safety and healthcare integrity.

The settlement underscores the importance of transparency in pharmaceutical marketing, reinforcing regulations meant to prevent conflicts of interest that could compromise patient care. Veloxis, while denying any wrongdoing, acknowledged the need to settle to avoid prolonged litigation. As the pharmaceutical industry continues to face scrutiny over marketing practices, this case serves as a reminder of the legal and ethical obligations that companies must uphold. The settlement will contribute to ongoing efforts to ensure compliance and restore trust in the industry.

For more details and the full reference, visit the source link below:

Read the complete article here: https://www.stl.news/veloxis-to-pay-46m-in-kickback-case/